Liposomes containing particulate materials

Details Liposomes containing particulate materials Liposomes containing particulate materials

1996-09-20

2001-11-27

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S234100, C424S240100, C424S246100, C424S258100, C424S093100, C264S004100, C264S004300, C264S004600

Reexamination Certificate

active

06322809

ABSTRACT:

The present invention relates to liposome preparations capable of use in administration of organic solvent labile materials, such as whole live or attenuated cells, to human or animal bodies. Such preparations have utility in delivery of labile bioactive materials whereby a slow release is provided which may be targeted to specific body areas. A method for the manufacture of such preparations is also provided.
BACKGROUND OF THE INVENTION
The use of liposomes in the administration of vaccine agents is well known, and their adjuvant activity has been demonstrated by numerous studies into immunopotentiation of a large variety of bacterial, viral, protozoan, protein and peptide vaccines; see reviews by Gregoriadis G (1990) Immunol Today, 11, 89-97 and Alving C R (1991) J Immunol Method, 140, p1-13.
These studies have all been carried out using liposomes produced by techniques which generate vesicles of submicron average diameter (see Gregoriadis G (ed) (1993) Liposome Technology, 2nd Edition, Volumes I-III CRC Press, Boca Raton, 1993) which are capable of accomodating peptides and proteins, but not capable of efficiency carrying larger vaccines. Such larger vaccines include a number of attenuated or killed viruses and bacteria such as measles, polio virus.
Bordetella pertussis,
Bacille Calmette-Guerin and
Salmonella typhi
(see Mimms C A et al (1993) Medical Microbiology, Chapter 36, Mosby).
Although most of these vaccines are highly immunogenic, there are circumstances where their administration in sufficiently large liposomes may be a preferred alternative. For instance, in the case of multiple vaccines consisting of a mixture of soluble and particulate (eg. microbial) antigens or vaccine formulations also containing cytokines, simultaneous presentation of all materials to immunocompetant cells via a common liposome carrier may be advantageous in terms of improving the immunogenicity to antigens.
Furthermore, liposomes incorporating antigenic material in their aqueous phase are known to prevent interaction of the antigen with its antibodies in pre-immunized animals and ensuing allergic reactions or antigen neutralisation (Gregoriadis and Allison (1974) FEBS Lett., 45, 71-74. It can thus be seen that liposomes could be beneficial if employed as carriers for administration of vaccines to infants for prophylaxis against agents for which maternal antibodies were present, eg, such as measles, or to individuals with hypersensitivity to vaccine contaminants.
It is known to incorporate particulate materials into large liposomes having average diameter up to 9.2 &mgr;m by methods wherein solvents such as chloroform are formed into spherules containing smaller water droplets (see Kim and Martin (1981) Biochimica et Biophysica Acta. 646, 1-9). Using this technique materials such as Collagen, DNA and bacterial (
Streptococcus salivarius
) were entrapped, but it was noted that labile globular proteins such as serum albumen and haemoglobin did not allow liposome formation, presumably due to surface denaturation, and that protein denaturation occurred. Such method is unsuitable for the encapsulation of labile materials due to the damaging and cytotoxic effects of the organic solvent, and certainly unsuitable for the encapsulation of whole (live) or attenuated bacteria, protozoa, viruses or multicellular animal or plant cells.
Methods for entrapping soluble materials in liposomes without use of organic solvents in the encapsulation step have been known for several years (see Kirby and Gregoriadis (1984) Liposome Technology, Vol. I, Gregoriadis (ed), CRC Press, Inc Boca Raton, Fla., pp19-28; Deamer and Uster (1983) Liposomes, Ostro M J (ed) Marcel Dekker, Inc, NY. pp.27-51; Deamer and Barchfield (1982) J Mol Evol 18, 203-206), and are based upon a method which dehydrates preformed liposomes then rehydrates them in the presence of the soluble materials. In these methods the soluble materials enter with water as the liposomes fuse together resulting in material being entrapped in multilamella liposomes. The liposomes used were 40 to 80 nm in diameter before freeze drying and the multilamellar product vesicle volume resulting was still smaller. Such volume and structure are unsuitable for encapsulating micrometer size and/or living materials, and entrapment levels for soluble drugs are not as high as for unilamella liposomes due to relatively low surface area for entry into the vesicles. The same technique has also been applied to small unilamella liposomes for the purpose of encapsulating aqueous solutions (see EP 0171710).
The aforesaid process is relatively mild and has been used to successfully encapsulate labile solutes such as factors VIII (see Kirby and Gregoriadis (1984) Biotechnology, 2, 979-984) and tetanus toxoid (Gregoriadis et al (1987) Vaccine, Vol 5, p145-151). It relies upon solute entering the liposomes as they form while rehydration water enters. Despite such work on solutes, there has still not been provided a method for the encapsulation of whole (live) or attenuated organisms, cells or other insoluble structures bearing labile entities, without damaging them; whether bacterial, protozoan, viral or otherwise.
Furthermore, no method has yet been provided for encapsulating water labile soluble materials in larger liposomes, whether unilamellar or multilamella, that would allow targeting at specific tissues with still higher quantities of material.


REFERENCES:
patent: 4201767 (1980-05-01), Fullerton
patent: 4396630 (1983-08-01), Riedl et al.
patent: 4532089 (1985-07-01), MacDonald
patent: 4619794 (1986-10-01), Hauser
patent: 4814270 (1989-03-01), Piran
patent: 5049390 (1991-09-01), Wojdani
patent: 5157207 (1992-10-01), Carlson
patent: 5422120 (1995-06-01), Kim
patent: 0 172 007 (1986-02-01), None
patent: 0 171 710 (1986-02-01), None
patent: 2 066 203A (1981-07-01), None
patent: 2066203 (1981-07-01), None
patent: 2 164 624 A (1986-03-01), None
patent: WO 86/01103 (1986-02-01), None
patent: 94/17786 (1994-08-01), None
Ohsawa et al., “A Novel Method For Preparing Liposome With A High Capacity To Encapsulate Proteinous Drugs : Freeze-Drying Method,”Chem. Pharm. Bull. 32(6) 2442-2445(1984).
Shimizu et al: “Encapsulation of chicken egg yolk immunoglobulin G (IgY) by liposomes,”Biosci-Biotechnol-Biochem, Sep. 1993; (abstract).
New: “Liposome, A Practical Approach,” pp. 56-59, 94-97,Preparation of liposomes.

Affiliated with

Also associated with

Rating

Liposomes containing particulate materials does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomes containing particulate materials, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomes containing particulate materials will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2586475